Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02599870 · ClinicalTrials.gov registry record · NA
Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures
A NA study, sponsored by AltheaDx.
- Terminated
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT02599870: Clinical Trial NA study, sponsored by AltheaDx.
NCT02599870 is a NA study that was terminated before completion, run by AltheaDx. The registered enrollment target is 56 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02599870, a NA study, was terminated before completion, sponsored by AltheaDx.
- TERMINATED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) guided treatment when implemented into the pre-operative process for patients undergoing an elective spinal surgical procedure and requiring post-operative acute pain management, as compared to a group of subjects with the same attributes without the guidance of PGx testing for their post-surgery pain management. This study will also evaluate whether PGx testing can reduce narcotic consumption, opioid-related adverse effects, time to mobilization, medical visits and costs.
Primary Outcome
Duration of the post-surgical hospital stay
Interventions
- GENETIC NeuroIDgenetix Test Panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-02 |
| Phase | NA |
Why NCT02599870 stopped before completion
NCT02599870 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which NeuroIDgenetix Test Panel is the first listed.
NCT02599870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02599870 about?
NCT02599870 is a clinical study titled "Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures". The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) guided treatment when implemented into the pre-operative process for patients undergoing an elective spinal surgical procedure and requiring post-operative acute pain management, as compared to a group of subjects with the ...
What is the current status of trial NCT02599870?
This trial is currently terminated. It is a NA study. The enrollment target is 56 participants. The study started on 2015-09. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02599870?
The interventions under investigation include: NeuroIDgenetix Test Panel (GENETIC).
Who is sponsoring clinical trial NCT02599870?
This trial is sponsored by AltheaDx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02599870's enrollment target sits among peer trials
56 1262nd of 2000 higher than 737 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia